An FDA inspection raises questions about Bristol Myers Squibb's liso-cel facility and the CVR, but analysts urge caution
For months, speculation over Bristol Myers Squibb and its $9 Celgene CVR has focused on whether the FDA would be able to inspect the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
